Novartis plans mega takeover: 12 billion for US biotech company!

Novartis plans mega takeover: 12 billion for US biotech company!

Big news from the biotech world: The pharmaceutical company Novartis plans to take over the US biotech company Avidity Biosciences. The purchase price for the company is around $12 billion. This decision was unanimously approved by the boards of directors of both companies. But before the takeover is finalized, both the competition authorities and Avidity's shareholders must give their approval. Novartis aims to complete the acquisition in the first half of next year, but until then both companies will remain independent SRF reported.

Avidity Biosciences is based in San Diego and specializes in RNA therapies targeting genetic neuromuscular diseases. The acquisition will not only give Novartis access to innovative RNA delivery platforms, but also expand the pipeline with new therapeutic candidates. Novartis is thus consolidating its strategy in neuroscience and shows once again that the biotech sector is still on the rise.

A new beginning in the biotech sector

The acquisition of Avidity isn't the only interesting development in the biotech industry. There have been several notable takeover attempts in recent months, particularly at companies like Evotec and BioNTech. Evotec has recently seen its share price fall, but has leveled off again on speculation and analyst valuations, with its price target raised to 11.90 euros by Canadian bank RBC. These positive forecasts contrast with the rather weak development in recent quarters. Evotec's annual general meeting demonstrated the company's innovative strength under the motto “Pioneering Drug Discovery”. Capital increases analyzed.

But BioNTech is also active: The company is planning a complete takeover of CureVac in order to strengthen its own portfolio in the area of ​​mRNA-based cancer therapies. This transaction could significantly advance BioNTech's efforts to develop innovative therapeutics. It is also expected that CureVac's location in Tübingen will be retained so that existing patent disputes can be resolved.

A look into the future

The biotech sector overall is showing promising signs of renewal. The combination of specialized deals and strategic acquisitions could not only open up new opportunities in drug development, but also boost the entire market. Whether the dreams of Avidity, BioNTech or Evotec become reality remains to be seen. But one thing is certain: there is still a lot of movement and even more potential in the exciting world of biotechnology.